Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H13FN2O5 |
| Molecular Weight | 259.2216 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2[18F])C(=O)NC1=O
InChI
InChIKey=GBBJCSTXCAQSSJ-HMQZJZAASA-N
InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1/i11-1
| Molecular Formula | C10H13FN2O5 |
| Molecular Weight | 259.2216 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15586282
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15586282
Clevudine F18 is a radioconjugate comprised of the synthetic pyrimidine analog clevudine (1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine, d-FMAU) labeled with the radioisotope fluorine F18. Upon administration, fluorine F18 clevudine is distributed and taken up by cells based on the rate of the cell’s DNA synthesis. The amount is then measured using positron emission tomography (PET). The compound is investigated as an imaging agent in prostate, breast cancers, and other malignant neoplasms.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map03030 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15586282 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. | 2005-01 |
|
| Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. | 2004-04 |
|
| Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. | 2003-04 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15586282
A dose of 355-385 MBq of [18F]FMAU was intravenously infused into patients over 60s.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15296672
Breast cancer cells were transduced with herpes simplex virus 1 thymidine kinase. Logarithmically growing cells were incubated with about 111 –148 KBq (3 - 4 uCi) of [18F]FMAU. Following incubation and removal of media, the cells were washed with phosphate-buffered saline (PBS, 3x10 mL) and treated with 0.3N perchloric acid. The acidic mixtures were cooled to 4°C for 10 min, centrifuged for 1 min at 14,000 rpm and the supernatant was separated. The cell pellets were washed twice with PCA (1 mL), centrifuged, and the acid soluble fractions, washings, and cell pellets were treated with complete counting scintillation cocktail. Radioactivity was counted in a liquid scintillation counter.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:31:35 GMT 2025
by
admin
on
Mon Mar 31 21:31:35 GMT 2025
|
| Record UNII |
O24SW9A8X6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60145502
Created by
admin on Mon Mar 31 21:31:35 GMT 2025 , Edited by admin on Mon Mar 31 21:31:35 GMT 2025
|
PRIMARY | |||
|
O24SW9A8X6
Created by
admin on Mon Mar 31 21:31:35 GMT 2025 , Edited by admin on Mon Mar 31 21:31:35 GMT 2025
|
PRIMARY | |||
|
1027764-69-7
Created by
admin on Mon Mar 31 21:31:35 GMT 2025 , Edited by admin on Mon Mar 31 21:31:35 GMT 2025
|
PRIMARY | |||
|
25024028
Created by
admin on Mon Mar 31 21:31:35 GMT 2025 , Edited by admin on Mon Mar 31 21:31:35 GMT 2025
|
PRIMARY |